Peptic Ulcer Drugs Market to Grow with a CAGR of 3.25% through 2029
Rising prevalence of peptic ulcers and expanding geriatric
population are factors driving the Global Peptic Ulcer Drugs Market in the forecast
period 2025-2029.
According to TechSci Research report, “Peptic Ulcer
Drugs Market – Global Industry Size, Share, Trends, Competition Forecast
& Opportunities, 2029”, the Global Peptic Ulcer Drugs Market stood at
USD 3.42 billion in 2023 and is anticipated to grow with a CAGR of 3.25% in
the forecast period, 2025-2029. Peptic ulcers
are painful sores that develop on the inner lining of the stomach, the small
intestine, or the esophagus. They can be caused by various factors, including
infection with Helicobacter pylori bacteria, long-term use of nonsteroidal
anti-inflammatory drugs (NSAIDs), smoking, and excessive alcohol consumption.
The global peptic ulcer drugs market is a significant segment within the
pharmaceutical industry, and it continues to witness growth driven by various
market drivers.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Global Peptic Ulcer Drugs Market”
One of the primary market drivers is the
increasing prevalence of peptic ulcers. Changes in lifestyle, dietary habits,
and stress have contributed to a rise in the incidence of peptic ulcers. This
trend has created a growing patient population seeking treatment, leading to
increased demand for peptic ulcer drugs. The world's population is
aging, with a significant proportion of individuals over the age of 65. Elderly
individuals are more susceptible to peptic ulcers due to a higher likelihood of
taking NSAIDs for chronic conditions and experiencing age-related changes in
the gastrointestinal tract. This demographic shift has boosted the demand for
peptic ulcer drugs, driving market growth.
The pharmaceutical industry continues to
invest in research and development to create more effective and safer drugs for
peptic ulcer treatment. New drug formulations, innovative delivery mechanisms,
and improved therapeutic options are emerging, which attract both patients and
healthcare providers. These advancements fuel market expansion by offering
better treatment outcomes and fewer side effects.
The Global Peptic Ulcer Drugs Market is segmented into
product type, disease indication, distribution channel and company.
Based on disease indication, the Duodenal Ulcer segment has
emerged as the predominant market leader. Duodenal ulcers are generally less likely to lead to
severe complications compared to gastric ulcers. This reduced risk makes them
more manageable and less burdensome for both patients and healthcare providers.
Medications
such as proton pump inhibitors (PPIs) and antibiotics have shown significant
efficacy in treating duodenal ulcers, leading to higher prescription rates.
These drugs help reduce stomach acid production and eradicate H. pylori
infection.
Based on region, North America segment is expected to
grow during the forecast period. The regulatory framework for
pharmaceuticals in North America, particularly the United States and Canada, is
considered one of the most rigorous and transparent in the world. This
regulatory environment ensures that peptic ulcer drugs are thoroughly tested
for safety and efficacy before they reach the market. While this may create a
challenging path for drug approval, it also enhances the credibility of North
American pharmaceutical companies in the global market. As a result, many
investors and international partners are drawn to the region, further boosting
the development of peptic ulcer drugs. North America is home to numerous pharmaceutical
companies and research institutions with a strong focus on gastrointestinal
diseases, including peptic ulcers. These organizations are at the forefront of
research and innovation in drug development, seeking more effective and safer
treatments. Collaborations between research institutions, universities, and
pharmaceutical companies have yielded promising results, leading to the
introduction of novel peptic ulcer drugs.
Major companies operating in Global Peptic Ulcer
Drugs Market are:
- Daewoong Pharmaceutical Co., Ltd
- Takeda Pharmaceutical Co., Ltd.
- Pfizer Inc.
- AstraZeneca plc.
- RedHill Biopharma Ltd.
- Zydus Lifesciences Limited
- ANI Pharmaceuticals, Inc. (Novitium Pharma LLC.)
- Boehringer Ingelheim International GmbH
- Eisai Co. Ltd.
- Yuhan Corporation
Download Free Sample Report
Customers can also request for 10%
free customization on this report
“The global peptic ulcer drugs market is on a growth
trajectory due to multiple market drivers, including an increasing prevalence
of peptic ulcers, expanding geriatric population, advancements in drug
development, and rising healthcare expenditure. As pharmaceutical companies
focus on innovation and expanding into emerging markets, the market is poised
to continue its upward trend. Moreover, the emphasis on early diagnosis and
awareness campaigns ensures that peptic ulcer patients have access to a wide
range of treatment options, further contributing to the market's expansion.,”
said Mr. Karan Chechi, Research Director with TechSci Research, a
research-based management consulting firm.
“Global Peptic Ulcer Drugs Market By Product Type (Proton
Pump Inhibitors, Potassium-Competitive Acid Blocker (P-CAB), Antacids, H2-
Antagonist, Antibiotics, Ulcer Protective), By Disease Indication (Gastitis,
Gastric Ulcer, Duodenal Ulcer, Gastroesophageal Reflux Disease (GERD)), By Distribution Channel (Hospital Pharmacies,
Retail Pharmacies, E-Commerce), By Region, By
Competition Forecast & Opportunities, 2019-2029F”, has evaluated
the future growth potential of Global Peptic Ulcer Drugs Market and provides
statistics & information on market size, structure and future market
growth. The report intends to provide cutting-edge market intelligence and help
decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Peptic Ulcer Drugs Market.
Contact Us-
TechSci Research LLC
420 Lexington Avenue, Suite
300,
New York, United States-
10170
M: +13322586602
Email: [email protected]
Website: www.techsciresearch.com